Abstract:Aim: To investigate the enhancing effects of chitosan with or without enhancers on nasal recombinant hirudin-2 (rHV2) delivery in vitro and in vivo , and to evaluate the ciliotoxicity of these formulations. Methods: The permeation-enhancing effect of various chitosan formulations was estimated by using the permeation coefficient of fluorescein isothiocyanate recombinant hirudin-2 (FITC-rHV2) across the excited rabbit nasal epithelium in vitro . The effect was further evaluated by measuring the blood concentration level after nasal absorption of FITC-rHV2 in rats. The mucosal ciliotoxicity of different formulations was evaluated with an in situ toad palate model. Results: Chitosan at a concentration of 0.5% with or without various enhancers significantly increased the permeability coefficient (P) and relative bioavailability (Fr) of FITC-rHV2 compared with the blank control. The addition of 1% sodium dodecylsulfate, 5% Brij35, 5% Tween80, 1.5% menthol, 1% glycyrrhizic acid monoammonium salt (GAM) or 4% Azone into the 0.5% chitosan solution resulted in a further increase in absorption ( P <0.05) compared with 0.5% chitosan alone. But co-administration of chitosan with 5% hydroxyl-propyl-beta-cyclodextrin(HP-β-CD), 5%lecithin or 0.1% ethylenediamine tetraacetic acid (EDTA) was not more effective than using the 0.5% chitosan solution alone. Chitosan alone and with 5% HP-β-CD, 0.1% EDTA, 1% GAM or 5% Tween80 was relatively less ciliotoxic. Conclusion: Chitosan with or without some enhancers was able to effectively promote the nasal absorption of recombinant hirudin, while not resulting in severe mucosal ciliotoxicity. A chitosan formulation system would be a useful approach for the nasal delivery of recombinant hirudin.

Hirudin: Administration Routes and Formulations

Pharmacological Activities and Mechanisms of Hirudin and Its Derivatives - A Review

Investigation on recombinant hirudin via oral route.

Pharmacodynamics and Pharmacokinetics of Recombinant Hirudin Via Four Non-Parenteral Routes

Progress and Prospect of Hirudin and Its Derivants Research

Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes.

A Novel Hirudin Derivative Characterized with Anti-Platelet Aggregations and Thrombin Inhibition.

Controlled Delivery of Recombinant Hirudin Based on Thermo-Sensitive Pluronic® F127 Hydrogel for Subcutaneous Administration: in Vitro and in Vivo Characterization

The Pharmacokinetics and Pharmacodynamics of Recombinant Hirudin-2 Nasal Spray

Molecular dynamic and pharmacological studies on protein‐engineered hirudin variants of Hirudinaria manillensis and Hirudo medicinalis

Pharmacokinetic study with N-Ile1-Thr2-63-desulfato-r-hirudin in rabbits by means of bioassay

Pharmacological Overview of Hederagenin and Its Derivatives

Microneedle patch-assisted transdermal administration of recombinant hirudin for the treatment of thrombotic diseases

Improving long circulation and procoagulant platelet targeting by engineering of hirudin prodrug

Permeation-enhancing Effects of Chitosan Formulations on Recombinant Hirudin-2 by Nasal Delivery in Vitro and in Vivo.

Molecular cloning of hirudin derivative cDNA gene and expression in mammalian cell

Research Progress of Low Molecular Weight Heparin

Self-regulated hirudin delivery for anticoagulant therapy

Recombinant neorudin and its active metabolite hirudin: the fate in vivo of a novel anticoagulant drug

A Novel Hirudin Derivative Inhibiting Thrombin Without Bleeding for Subcutaneous Injection.

Engineering a “three-in-one” hirudin prodrug to reduce bleeding risk: A proof-of-concept study